[HTML][HTML] The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway
AL Catapano, N Papadopoulos - Atherosclerosis, 2013 - Elsevier
Monoclonal antibodies (mAbs) are established therapies for many conditions, including
cancers, autoimmune conditions and infectious diseases. mAbs can offer benefits over …
cancers, autoimmune conditions and infectious diseases. mAbs can offer benefits over …
[HTML][HTML] The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions
The secretory proprotein convertase (PC) family comprises nine members: PC1/3, PC2,
furin, PC4, PC5/6, PACE4, PC7, SKI-1/S1P, and PCSK9. The first seven PCs cleave their …
furin, PC4, PC5/6, PACE4, PC7, SKI-1/S1P, and PCSK9. The first seven PCs cleave their …
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation
Background—Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates low-density
lipoprotein (LDL) receptor (LDLR) degradation, thus influencing serum cholesterol levels …
lipoprotein (LDL) receptor (LDLR) degradation, thus influencing serum cholesterol levels …
[HTML][HTML] Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)
M Canuel, X Sun, MC Asselin, E Paramithiotis, A Prat… - PloS one, 2013 - journals.plos.org
Elevated LDL-cholesterol (LDLc) levels are a major risk factor for cardiovascular disease
and atherosclerosis. LDLc is cleared from circulation by the LDL receptor (LDLR). Proprotein …
and atherosclerosis. LDLc is cleared from circulation by the LDL receptor (LDLR). Proprotein …
Highly fluorescent nanodiamonds protein‐functionalized for cell labeling and targeting
Fluorescent nanodiamond (FND) is attracting much attention as a bioimaging agent
because of its inherent biocompatibility and superior optical properties (eg, excellent …
because of its inherent biocompatibility and superior optical properties (eg, excellent …
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
S Poirier, G Mayer - Drug design, development and therapy, 2013 - Taylor & Francis
Proprotein convertase subtilisin/kexin type 9 (PCSK9) directly binds to the epidermal growth
factor-like repeat A domain of low-density lipoprotein receptor and induces its degradation …
factor-like repeat A domain of low-density lipoprotein receptor and induces its degradation …
IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor
E Scotti, M Calamai, CN Goulbourne… - … and cellular biology, 2013 - Am Soc Microbiol
The low-density lipoprotein receptor (LDLR) is a critical determinant of plasma cholesterol
levels that internalizes lipoprotein cargo via clathrin-mediated endocytosis. Here, we show …
levels that internalizes lipoprotein cargo via clathrin-mediated endocytosis. Here, we show …
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies
NG Seidah - Current pharmaceutical design, 2013 - ingentaconnect.com
The discovery of PCSK9 in 2003 and its identification as the third protagonist responsible for
ADH opened many new avenues of research in the cardiovascular field. Liver PCSK9 binds …
ADH opened many new avenues of research in the cardiovascular field. Liver PCSK9 binds …
Proprotein C onvertases S ubtilisin/K exin T ype 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (第9 型前蛋白转换酶—枯草溶菌素/蛋白酶K, 一 …
摘要第9 型前蛋白转换酶—枯草溶菌素/蛋白酶K (PCSK9) 是一种丝氨酸内蛋白酶.
它是一种生物合成的酶原, 它先将自己裂解一次, 接着变成一种跨膜蛋白的护送蛋白 …
它是一种生物合成的酶原, 它先将自己裂解一次, 接着变成一种跨膜蛋白的护送蛋白 …
[PDF][PDF] PCSK9 inhibition-a novel mechanism to treat lipid disorders?
Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of
cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through …
cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through …